COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

Stefan Hohaus, Luciana Teofili, Mario Balducci, Stefania Manfrida, Angelo Pompucci, Francesco D'Alo', Giuseppina Massini, Luigi Maria Larocca, Roberto Marra, Sergio Storti
  • Luciana Teofili
    Affiliation not present
  • Mario Balducci
    Affiliation not present
  • Stefania Manfrida
    Affiliation not present
  • Angelo Pompucci
    Affiliation not present
  • Francesco D'Alo'
    Affiliation not present
  • Giuseppina Massini
    Affiliation not present
  • Luigi Maria Larocca
    Affiliation not present
  • Roberto Marra
    Affiliation not present
  • Sergio Storti
    Affiliation not present

Abstract

Chemotherapy including high-dose methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treated using a combined treatment modality, including HD-MTX (3.5 g/m2 for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (HD-AraC) (2g/m2 for 4 doses for 2 cycles). Complete remission was obtained in 23 of 34 assessable patients (67%), and overall and disease-free survival rates were 24% and 46%, respectively, without differences between treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 (77%) patients, resulting in 3 toxic deaths. Our study indicates that addition of HD-AraC may not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less toxic therapies are warranted.

Keywords

Lymphoma

Full Text:

PDF
HTML
Submitted: 2014-06-11 11:44:36
Published: 2009-12-14 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
81

Views:
PDF
51
HTML
872

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Ā 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPressĀ®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185